Skip to content

Clinical trial to evaluate the efficacy and safety of laparoscopic assisted hysterectomy and radical hysterectomy for cervical cancer

Clinical trial to evaluate the efficacy and safety of laparoscopic assisted hysterectomy and radical hysterectomy for cervical cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074107
Enrollment
Unknown
Registered
2023-07-31
Start date
2023-07-31
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Hysterectomy and Radical Cervical Cancer

Interventions

Sponsors

First Affiliated Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of benign uterine lesions, including uterine smooth muscle tumors, abnormal uterine bleeding, Atypical hyperplasia of endometrium, precancerous lesion of the neck of uterus, adenomyosis, etc., which are considered to require hysterectomy or diagnosed as cervical cancer, and have clinical stage IA, IB, or IIA (FIGO stage); 2. Age 18-75 years (inclusive); 3. Consent to sign informed consent form and follow doctor's advice, regular follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Patients with cardiovascular and cerebrovascular diseases, blood system diseases, coagulation disorders and diabetes mellitus, which can not be controlled and can not meet the operation standards; 2. Preoperatively received radiotherapy and / or immunotherapy and / ortargeted therapy; 3. Liver and kidney function can not reach the standard of operation; 4. Have immune system disease, can not meet the operation criteria; 5. Intolerant to anesthesia and surgery; 6. Severe uncontrolled disease or acute infection; 7. Patients with mental illness; 8. Incomplete participation in other investigational drug or device clinical trials; 9. Those with reproductive needs; 10. Lactation and pregnancy; 11. Patients whom the investigator considers inappropriate for this program.

Design outcomes

Primary

MeasureTime frame
Rate of unconverted surgery;

Secondary

MeasureTime frame
Urination function;Exhaust time;Paraffin pathological margin;Number of lymph nodes removed;Postoperative hospital stay;Postoperative pain score;Surgeon's satisfaction;

Countries

China

Contacts

Public ContactTang Junying

First Affiliated Hospital of Chongqing Medical University

tangjy_cqmu@sina.com+86 135 0835 1600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026